Heart risk check for schizophrenia drugs

NCT ID NCT00288353

Terminated Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see how two antipsychotic drugs, aripiprazole and ziprasidone, affect heart risk in people with schizophrenia, schizoaffective disorder, or bipolar disorder. Researchers measured blood fats and heart electrical changes in 48 adults over 12 months. The trial was stopped early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aripiprazole and ziprasidone
What this could lead to: If successful, this could help doctors choose antipsychotics that lower heart risk in patients with schizophrenia or bipolar disorder.
What could go wrong: This small, terminated Phase 3 trial may not provide clear results due to early stopping, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar disorder metabolic syndrome X Psychotic Disorders schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIPOLAR DISORDER SCHIZOAFFECTIVE DISORDER SCHIZOPHRENIA

Contacts and locations

Locations

Vanderbilt Psychiatric Hospital

Nashville, Tennessee, 37212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.